Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters

INTRODUCTION: Benefits of disease-modifying anti-rheumatic drugs (DMARD) in early rheumatoid arthritis patients (ERAP) will be achieved if patients follow prescribed treatment. Objective was to investigate whether timing of first non-persistence period and/or duration of persistence during the first...

Descripción completa

Detalles Bibliográficos
Autores principales: Contreras-Yáñez, Irazú, Pascual-Ramos, Virginia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499189/
https://www.ncbi.nlm.nih.gov/pubmed/26162892
http://dx.doi.org/10.1186/s13075-015-0697-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499189/
https://www.ncbi.nlm.nih.gov/pubmed/26162892
http://dx.doi.org/10.1186/s13075-015-0697-z

Ejemplares similares